NCT06784752 2026-03-06
NETTER-3
Novartis
Phase 3 Recruiting
Clinical Trials
34 trialsNCT06295952 2026-03-04
A Study of Pasireotide in People With Prolactinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
NCT01313559 2025-04-30
Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Thomas Jefferson University
Phase 2 Terminated
NCT06456359 2025-01-13
PAMSARC
University Hospital Heidelberg
Phase 2 Recruiting
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT04826432 2024-02-08
PASIREOCHIP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT01253161 2023-03-06
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02779257 2022-03-04
Pasireotide Treatment for Neuroendocrine Tumor
University of Maryland, Baltimore
Phase 4 Withdrawn
NCT02215070 2021-11-17
Pasireotide in Prevention of GI Toxicity
Duke University
Phase 2 Completed
NCT01563354 2021-04-02
LUNA
Novartis
Phase 2 Completed
NCT01468532 2021-03-25
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT01270321 2021-02-17
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Emory University
Phase 2 Completed
NCT01646684 2020-12-21
Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer
Novartis
Phase 1 Completed
NCT01385956 2020-09-28
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01915303 2020-09-18
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Novartis
Phase 2 Terminated
NCT02775227 2020-08-24
HYPAR
Helsinki University Central Hospital
Phase 4 Active not recruiting
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT01469572 2018-10-18
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Emory University
Phase 1 Completed
NCT02021942 2018-02-05
Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
University of Regensburg
Phase 2 Completed
NCT01252251 2017-08-01
RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01639352 2017-07-12
Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Completed
NCT01356862 2017-01-25
SOM 230
Alliance Pour La Recherche en Cancerologie
Phase 2 Completed
NCT01372644 2016-12-05
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
NYU Langone Health
Phase 1 Completed
NCT01617733 2016-11-02
Pasireotide Therapy in Patients With Nelson's Syndrome
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT00804336 2016-10-19
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01620138 2016-08-22
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Universidade Federal do Rio de Janeiro
Phase 2/3 Completed
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT01625520 2016-04-25
SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer
Federico II University
Phase 2 Completed
NCT01329289 2016-02-12
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
University of Pittsburgh
Phase 2 Withdrawn
NCT00994110 2016-02-01
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Memorial Sloan Kettering Cancer Center
Phase 3 Completed
NCT00813592 2014-06-11
Phase II Study of SOM230 in Patients With Recurrent or Progressive Meningioma
University of Utah
Phase 2 Terminated
NCT00088595 2012-06-04
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Novartis
Phase 2 Completed
NCT01417806 2011-08-16
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
South Florida Veterans Affairs Foundation for Research and Education
Phase 2 Unknown